Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pendulum Glucose Control
- Development stage
- Phase 2
- Lead developer
- Pendulum Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Pendulum Glucose Control** is an orally administered proprietary five-strain synbiotic dietary supplement developed by Pendulum Therapeutics. The WBF-038 formulation contains *Akkermansia muciniphila*, *Anaerobutyricum hallii*, *Bifidobacterium infantis*, *Clostridium beijerinckii*, and *Clostridium butyricum*, together with chicory inulin as a prebiotic. It is intended to modulate the intestinal microbiome and promote microbial fermentation and butyrate production, which may support gut-barrier and metabolic functions and indirectly stimulate endogenous GLP-1 release. Clinical studies are evaluating the formulation for metabolic health, prevention of aromatase inhibitor-associated bone loss in hormone receptor-positive breast cancer, and mitigation of gastrointestinal toxicity during pelvic radiation. ([anzctr.org.au](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621001171808))
- Brand names
- Pendulum Glucose Control
- Other names
- PGCPendulum WBF-038Probiotic/Prebiotic Formulation WBF-038
Beyond the preview
Go deeper on Pendulum Glucose Control.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pendulum Glucose Control.